Summary
Eli Lilly & Company (LLY) filed an 8-K on December 13, 2022, to announce its financial guidance for the fiscal year 2023. This filing is primarily focused on providing forward-looking financial expectations to investors, which were also discussed during a teleconference for analysts and media held on the same day. The press release containing this guidance is attached as Exhibit 99.1 to the 8-K. While the 8-K itself does not contain detailed financial results or operational updates, it serves as the official channel for disseminating the company's strategic financial outlook for the upcoming year. Investors should refer to the attached Exhibit 99.1 for the specific figures and assumptions underpinning Lilly's 2023 financial projections, which will be crucial for evaluating the company's anticipated performance and growth trajectory.
Key Highlights
- 1Eli Lilly & Company (LLY) announced its 2023 financial guidance via an 8-K filing.
- 2The guidance was released on December 13, 2022, alongside a press conference.
- 3The press release containing the 2023 financial guidance is included as Exhibit 99.1.
- 4The filing serves to inform investors about the company's expected financial performance for the upcoming fiscal year.
- 5Information furnished under Item 2.02 is not considered 'filed' for Section 18 purposes, limiting liability.
- 6The company held a teleconference for analysts and media to discuss the 2023 guidance.